Movers & Shakers: Lyell Immunopharma, Radionetics Oncology, AlivaMab Discovery and More
Life science companies made adjustments to their leadership teams with multiple appointments for chief commercial officers, chief business officers, and more with this week’s Movers & Shakers.
New York-based Intrommune Therapeutics added two members to its leadership team. Stuart Loesch, who currently serves as chief commercial officer, was named president and William Berger was tapped to serve as head of clinical development.
Loesch’s responsibilities with the company will expand under his new title. Loesch will continue to manage all commercial activities, as well as oversee the clinical, regulatory and manufacturing functions of Intrommune’s pipeline, including INT301 for peanut-allergic patients, which is currently in clinical development.
Throughout his career, Loesch has held roles at multiple pharmaceutical companies, including Altana Pharmaceuticals, Nycomed, Schering-Plough, Merck, Teva and Meda Pharmaceuticals. Before joining Intrommune in 2021, Loesch served as vice president of marketing, BD and commercial strategy at ALK.
A world-renowned allergist, Berger founded the Allergy and Asthma Associates of Southern California Medical Group. He also established the Southern California Research Center, which focused on respiratory and allergy clinical research projects.
Discovery Life Sciences
Suso J. Platero joined Alabama-based Discovery Life Sciences as chief scientific officer. Platero brings over 20 years of leadership in managing biomarker development organizations at leading pharmaceutical and diagnostics companies.
Before joining Discovery, Platero served as vice president of biomarkers, imaging, and diagnostics at Vertex Pharmaceuticals. Before that, Platero led the development of a biomarker solution center for cell and gene therapy at Labcorp. He also had prior leadership at Janssen and Bristol Myers Squibb.
Matthew Caldemeyer was appointed chief business officer of San Diego-based Recludix Pharma. He most recently served as vice president of business development at Shanghai-based Everest Medicines.
Caldemeyer previously served as head of business development at Ambrx and as director of the corporate strategy and business development at Array BioPharma. Before that, he held roles of increasing responsibility in strategy and corporate development at Amgen, and before that, at Eli Lilly.
Michael Meier is the new vice president of sales and marketing at Atlanta-based Femasys. His hiring coincided with the commercial availability of FemCerv, an endocervical tissue sampler designed to improve women’s health.
Meier was previously the head of business development and payor relations at Gravity Diagnostics. Prior to that, he served as vice president of sales and commercialization at Caldera Medical.
AlivaMab Discovery Services
Larry Green reassumed the role of chief executive officer at AlivaMab. He was the founding CEO of the San Diego-based company. Green will continue to serve as CEO of Ablexis, LLC.
He takes over the role from Justin Mika, who held the position for the past two years.
Ted A. Marcuccio joins Virginia-based Kaléo as chief business officer. Marcuccio previously held a similar role at Summit Biosciences prior to joining Kaléo. He also held leadership positions at Meridian Medical Technologies, King Pharmaceuticals and Baxter International.
As CBO, Marcuccio is expected to help the company scale through product acquisition and partnership deals for its Aerio Auto-Injection Platform.
Umesh Gangadharmath joins San Diego-based Radionetics as SVP of technical operations.
Gangadharmath previously served as chief operating officer at Optimal Tracers, a radiopharmaceutical-focused contract development and manufacturing company. He also served as a member of the United States Pharmacopeia Radioactive Drugs Expert Panel and played a key role in developing a molecular imaging program at Loma Linda University Medical Center.
Karin Schmitt joined U.K.-based Mursla as chief operating officer. Schmitt previously held leadership roles in the U.S. at Exelixis and Millennium Pharmaceuticals and in the U.K. at Thermo Fisher Scientific, Horizon Discovery Group, PredictImmune, and most recently Mogrify.
Prior to joining Lyell, Thompson was executive vice president and general counsel at Gritstone bio. He was also general counsel for Opiant Pharmaceuticals. Previously, as the vice president of law for Actelion Pharmaceuticals. Before that, Thompson was the associate general counsel at Abraxis Bioscience before its acquisition by Celgene.